EnteroBiotix
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Phoenix House Phoenix Crescent Strathcly...Phone Number
+44 1698501370Website
www.enterobiotix.comRevenue
$8.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About EnteroBiotix
EnteroBiotix is a clinical-stage biopharmaceutical company building a leading position in full-spectrum microbiome therapeutics. Its lead product, EBX-102-02, has the potential to be the first disease-modifying therapy for irritable bowel syndrome and is progressing into Phase 2b development (RISE trial) following positive Phase 2a data (TrIuMPH trial).Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EnteroBiotix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if EnteroBiotix has recently received funding, and reach out quickly before it becomes old news!
EnteroBiotix, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when EnteroBiotix launches new products
Click to see if EnteroBiotix had a recent Job posting/layoffs
Earning: See what the market has to say on EnteroBiotix recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if EnteroBiotix is spiking on competitors!
Funding: Get notified immidiatlly once EnteroBiotix has new funding data
Congratulate Masked Content for being promoted to Masked Content at EnteroBiotix
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to EnteroBiotix
Compare insights from companies similar to EnteroBiotix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
EnteroBiotix
$8.5M
11-50
Private
$91.6M
2017
N/A
Company Profile Activity
Activity Insights
EnteroBiotix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
EnteroBiotix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about EnteroBiotix.
EnteroBiotix financials insights
Gather financial insights about EnteroBiotix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Angel/Seed
$4M
2021
Series A
$21.5M
2024
Debt
$14.6M
Private Equity
$19.8M
2025
Private Equity
$1.4M
2026
Private Equity
$5.3M
Unspecified
$25M
EnteroBiotix Tech Stack
A closer look at the technologies used by EnteroBiotix
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
, according to a recent Form D filing, has secured $1,389,676 in Private Equity funding.
Funding
Funding
Funding
Funding
EnteroBiotix News & Media
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome
Glasgow, Scotland – 29 April 2026. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome therapeutic, into Phase 2b development for Irritable Bowel Syndrome with Constipation (IBS-C).EnteroBiotix Announces Completion of Enrolment in Phase 2a Trial Evaluating EBX-102-02 Prior to Allogeneic Stem Cell Transplantation
GLASGOW, United Kingdom, March 10, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class microbiome therapies, today announced that the investigator-initiated Phase 2a MAST trial (Intestinal Microbiota Transplant prior to Allogeneic Stem Cell Transplantation) has completed its enrolment of 50 adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) for defined haematological malignancies. Participants receive EEnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome
GLASGOW, Scotland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EnteroBiotix”), a clinical-stage biopharmaceutical company focused on developing best-in-class therapies for gut health, today announced positive final results from TrIuMPH, a Phase 2a clinical trial evaluating EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic, in patients with irritable bowel syndrome with constipation (IBS-C) or diarrhoea (IBS-D).
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding EnteroBiotix
Sign Up For FreeTo access detailed company insights
EnteroBiotix is a clinical-stage biopharmaceutical company building a leading position in full-spectrum microbiome therapeutics. Its lead product, EBX-102-02, has the potential to be the first disease-modifying therapy for irritable bowel syndrome and is progressing into Phase 2b development (RISE trial) following positive Phase 2a data (TrIuMPH tr... Read More
